About Freenome
Freenome is a biotechnology company focused on revolutionizing cancer detection through its multiomics platform and artificial intelligence (AI). The company aims to detect cancer in its earliest, most treatable stages via a routine blood draw, making screening more accessible for everyone. Their proprietary platform integrates molecular biology, computational biology, and machine learning to analyze various biological signals, including cell-free DNA (cfDNA) methylation patterns, immune cell fragments, and metabolic markers. This multimodal approach is designed to overcome the inherent heterogeneity of cancer, allowing for the identification of subtle cues associated with the disease even in its nascent stages.
For physicians, Freenome’s technology offers the potential for non-invasive, blood-based screening tests for various cancers, including colorectal and lung cancer. The company’s lead product, SimpleScreen™ CRC, is a blood-based screening test for colorectal cancer, which has undergone clinical validation through the PREEMPT CRC Study. Freenome is also developing tests for lung cancer and a broader portfolio of single-cancer and multi-cancer detection tests. Their approach involves rigorous clinical programs to drive the discovery, development, and validation of these early cancer detection tests, with the goal of expanding access to screening and improving patient outcomes.
Focus Areas
Business Intelligence
| Technology | Multiomics platform (integrating cell-free DNA, methylation, proteins, cfRNA, autoantibodies, cfDNA fragmentomics, nucleosome footprinting) with advanced computational biology, machine learning, and deep learning models. Cloud-native infrastructure with AI operating system. |
What Physicians Need to Know
For physicians, Freenome's blood-based tests like SimpleScreenu2122 CRC offer a convenient and accessible option for cancer screening, potentially increasing patient adherence to screening guidelines. The non-invasive nature of a simple blood draw can overcome barriers associated with traditional screening methods, such as discomfort or logistical challenges. A positive result from SimpleScreenu2122 CRC should be followed by a colonoscopy. The investigational SimpleScreenu2122 Lung test aims to complement current lung cancer screening guidelines by identifying high-risk individuals who would benefit from low-dose CT. Freenome's Personalized Cancer Detection approach combines risk-based screening with indication-specific blood tests, aiming for more individualized and data-driven screening.
Freenome actively partners with healthcare organizations, academic institutions, and biopharma companies to integrate their technology and software platform into clinical care. They collaborate on biomarker development, clinical study design, and population health analytics, including real-world data integration and EMR integration services. Freenome also leverages cloud technologies like Google Cloud for data storage, analytics (BigQuery), and machine learning model deployment (GKE), and has partnered with NVIDIA to accelerate their AI and deep learning initiatives. They have strategic partnerships with companies like Abbott for commercialization in the U.S. and Roche for international markets.
What the Web Says
Freenome is a biotechnology company focused on early cancer detection through blood-based tests, utilizing a multiomics platform and AI/machine learning. The company has received significant funding and is actively conducting clinical trials for its SimpleScreen CRC test, which has shown improved performance in detecting colorectal cancer and precancerous lesions. While employee reviews generally highlight a positive culture and mission, some concerns exist regarding management and compensation.
Overall: MixedStrengths
- Incredible mission focused on saving lives through early cancer detection.
- Positive work culture with passionate and empathetic colleagues.
- Strong emphasis on culture during the interview process.
- Free meals and snacks available for employees.
- Advanced multiomics platform combined with AI/ML for sensitive cancer detection.
- Improved performance of their colorectal cancer screening test in recent studies.
Limitations
- Leadership struggles with communication and decision-making.
- Managers in some departments are perceived as overworking lab techs without meeting compensation or career needs.
- Compensation may be lower than current market rates, with stock options offered after one year.
- Layoffs have occurred, potentially due to disappointing test results and unsustainable spending.
- Some concerns about professionalism among managers.
- The company is clinical-stage and pre-revenue, with an uncertain path to profitability.
Based on reviews from: Comparably, Zippia, SimplyHired, Indeed.com, MedTech Dive, PR Newswire, Nanalyze, Reddit, Bain Capital Life Sciences
Last updated: 2026-08-30
Videos
News, demos, and interviews about Freenome.
Videos load interactively. If none appear, search YouTube for Freenome →
Frequently Asked Questions
Investors
Who's funded Freenome.
Related Companies
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]
The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]
Prenaital is an AI-driven healthcare company focused on revolutionizing maternal care by improving the early detection and management of high-risk pregnancies. Their AI models analyze ultrasound images to identify at-risk pregnancies, including those with abnormal fetal growth and a risk of preterm birth, with significantly higher accuracy than current clinical practices—detecting 25-50% more high-risk cases. […]
PHQ Screeners is a free, open-access resource maintained by Pfizer, providing a comprehensive suite of Patient Health Questionnaire (PHQ) and Generalized Anxiety Disorder (GAD-7) screening instruments. These tools were developed by Drs. Robert L. Spitzer, Janet B.W. Williams, and Kurt Kroenke with an educational grant from Pfizer, and are widely utilized in primary care and […]
NeurixaHealthAI™ is a healthcare AI company dedicated to eliminating administrative waste in the healthcare system, which they estimate to be $1.1 trillion annually. They offer a production-ready healthcare intelligence platform designed to simplify operations, improve outcomes, and accelerate the journey from patient care to financial performance. The platform is not a collection of point solutions […]